# ESMO-MCBS v2.0: Advances, challenges, and perspectives in the assessment of clinical benefit in oncology

**Authors:** Ezequiel Mauro, Miquel Serra-Burriel

PMC · DOI: 10.1016/j.jhepr.2025.101553 · JHEP Reports · 2025-09-24

## Full-text entities

- **Genes:** AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** Cancer (MESH:D009369), NPH (MESH:C580335), OS (MESH:D011475), toxicity (MESH:D064420), HCC (MESH:D006528)
- **Chemicals:** Ramucirumab (MESH:C543333), cabozantinib (MESH:C558660), atezolizumab (MESH:C000594389), bevacizumab (MESH:D000068258), regorafenib (MESH:C559147), ESMO-MCBS (-), Durvalumab (MESH:C000613593), Lenvatinib (MESH:C531958), tremelimumab (MESH:C520704)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12541619/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12541619/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12541619/full.md

---
Source: https://tomesphere.com/paper/PMC12541619